BioCryst Pharmaceuticals. has been granted a patent for compounds that inhibit ALK2 kinase, including specific formulas and their salts. These compounds are intended for use in treating conditions like fibrodysplasia ossificans progressiva, along with related pharmaceutical compositions and methods. GlobalData’s report on BioCryst Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on BioCryst Pharmaceuticals, Cancer treatment biomarkers was a key innovation area identified from patents. BioCryst Pharmaceuticals's grant share as of July 2024 was 39%. Grant share is based on the ratio of number of grants to total number of patents.
The granted patent US12054492B2 encompasses a series of claims related to specific chemical compounds represented by various structural formulas. The primary claim outlines a compound defined by formula (I) or (II), with subsequent claims detailing variations of these compounds through additional structural representations (Ia, IIa, Ib, IIb, etc.). The claims further specify particular characteristics of these compounds, such as the presence of certain functional groups (e.g., NH, CH2) and substituents (e.g., alkyl, aryl, hydroxyalkyl). Notably, the patent includes claims that describe pharmaceutical compositions containing these compounds and their potential therapeutic applications.
In addition to the structural claims, the patent outlines methods for utilizing these compounds in medical treatments. Specifically, it claims methods for inhibiting ALK2 kinase and treating conditions such as fibrodysplasia ossificans progressiva and gliomas, including the specific subtype diffuse intrinsic pontine glioma. The claims emphasize the therapeutic effectiveness of the compounds when administered in appropriate dosages. Overall, the patent presents a comprehensive framework for the development and application of these compounds in pharmaceutical contexts, highlighting their potential utility in treating serious medical conditions.
To know more about GlobalData’s detailed insights on BioCryst Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
